(Q43054908)

English

Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months

scientific article published on 26 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 November 2017

Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months (English)

1 reference

Europe PubMed Central

13 November 2017

0 references

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

author name string

Lourdes Ibáñez

1

1 reference

Europe PubMed Central

13 November 2017

Abel López-Bermejo

2

1 reference

Europe PubMed Central

13 November 2017

Marta Díaz

3

1 reference

Europe PubMed Central

13 November 2017

Goya Enríquez

4

1 reference

Europe PubMed Central

13 November 2017

Luis Del Río

5

1 reference

Europe PubMed Central

13 November 2017

Francis De Zegher

6

1 reference

Europe PubMed Central

13 November 2017

publication date

26 May 2010

1 reference

Europe PubMed Central

13 November 2017

Gynecological Endocrinology

1 reference

Europe PubMed Central

13 November 2017

26

1 reference

Europe PubMed Central

13 November 2017

12

1 reference

Europe PubMed Central

13 November 2017

869-873

1 reference

Europe PubMed Central

13 November 2017

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Clinical review: Identifying children at risk for polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Low-dose flutamide for women with androgen excess: anti-androgenic efficacy and hepatic safety

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.487589

21 January 2018

Identifiers

10.3109/09513590.2010.487589

1 reference

Europe PubMed Central

13 November 2017

1 reference

Europe PubMed Central

13 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43054908&oldid=1978817875"